FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2042990257> ?p ?o ?g. }

• W2042990257 endingPage "E26" @default.
• W2042990257 startingPage "E26" @default.
• W2042990257 abstract "Back to table of contents Previous article Next article LettersFull AccessImprovement in Psychotic Symptoms and Social Functioning After Augmentation of Paliperidone With Clozapine in a Patient With Schizoaffective DisorderYi-Cheng Hou, MSc, and Chien-Han Lai, M.D.Yi-Cheng HouSearch for more papers by this author, MSc, and Chien-Han LaiSearch for more papers by this author, M.D.Published Online:1 Jan 2014https://doi.org/10.1176/appi.neuropsych.13010010AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail To the Editor: “Mrs. B,” who had significant depression symptoms and psychotic symptoms with significant exacerbations of self-care in the past 7 months, was diagnosed with schizoaffective disorder, depressed subtype, because of persistent psychotic symptoms even after response of her depression with mirtazapine 60 mg/day. She still had significant psychotic symptoms even after several kinds of antipsychotics, such as risperidone 8 mg/day, olanzapine 30 mg/day, and aripiprazole 30 mg/day during her 1-month hospitalization (Brief Psychiatric Rating Scale−18 items [BPRS−18] scores: 56, especially in items of uncooperativeness [6 points], hallucinatory behaviors [7 points], hostility [6 points] and suspiciousness [6 points]). Because of apparent treatment-resistance, the antipsychotic was switched to clozapine 200 mg/day gradually, with excessive salivation side effects. The responses of her psychotic symptoms still remained limited after using clozapine (BPRS−18 scores: 53). Her self-care, social, and occupational functioning also did not improve (Social and Occupational Function Assessment Scale [SOFA] score: 20].Because of the persistence of psychotic symptoms even under clozapine, we added paliperidone 9 mg/day to assist the control of psychotic symptoms. She had significant improvement of psychotic symptoms (BPRS scores: 53 > 38; items of uncooperativeness [6 > 2], hallucinatory behaviors [7 > 3], hostility [6 > 3] and suspiciousness [6 > 3]) after augmentation of paliperidone for 1 month. No significant side effects after combinations of clozapine and paliperidone were observed. After discharge, she could go to market to buy commodities and had better ability for self-care. Her social functioning also showed significant improvement (SOFA score: 20 > 55).DiscussionThis patient had significant improvements of treatment-resistant psychotic symptoms after augmentation of paliperidone with clozapine. It might be related to the serotonin 5-HT2A antagonism and dopamine D2 antagonism effects of paliperidone. Besides, paliperidone is effective in the treatment of schizoaffective disorder.1 Paliperidone has been reported to improve personal and social functioning in schizophrenia patients.2 Paliperidone also has a better profile of side effects and less harm.3 Healthy volunteers using paliperidone had better performance on Stroop Word–Color tests than on risperidone or placebo. This suggests that paliperidone might improve cognitive functioning.4 Kim et al.’s report on schizophrenia patients also supports the role of paliperidone in the improvement of neurocognitive and social functioning.5 In this patient, I hypothesized that paliperidone augmentation might enhance the clozapine’s 5HT2A antagonism with better results in social and occupational functions. Also, paliperidone might enhance D2 antagonism effects of clozapine because of paliperidone’s higher affinity for D2 receptors, which will decrease psychotic symptoms.6 To my knowledge, this is first case report about clozapine and paliperidone combination therapy in schizoaffective disorder. This combination might be an alternative for treatment-resistant schizoaffective patients.Department of Nutrition, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan, ROCCorresponding author: Chien-Han Lai, M.D. Department of Psychiatry, Cheng Hsin General Hospital, Taipei City, Taiwan, ROCe-mail address: [email protected]comReferences1 Yang LP: Oral paliperidone: a review of its use in the management of schizoaffective disorder. CNS Drugs 2011; 25:523–538Crossref, Medline, Google Scholar2 Huang MW, Yang TT, Ten PR, et al.: Effects of paliperidone extended release on the symptoms and functioning of schizophrenia. BMC Clin Pharmacol 2012; 12:1Crossref, Medline, Google Scholar3 Gopal S, Berwaerts J, Nuamah I, et al.: Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia. Neuropsychiatr Dis Treat 2011; 7:93–101Crossref, Medline, Google Scholar4 Yoon KS, Park TW, Yang JC, et al.: Different safety profiles of risperidone and paliperidone extended-release: a double-blind, placebo-controlled trial with healthy volunteers. Hum Psychopharmacol 2012; 27:305–314Crossref, Medline, Google Scholar5 Kim SW, Chung YC, Lee YH, et al.: Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial. Int Clin Psychopharmacol 2012; 27:267–274Crossref, Medline, Google Scholar6 Bishara D, Taylor D: Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy, and tolerability. Drugs 2008; 68:2269–2292Crossref, Medline, Google Scholar FiguresReferencesCited byDetailsCited byClozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study16 July 2020 | European Psychiatry, Vol. 63, No. 1Clozapine28 June 2014 | Reactions Weekly, Vol. 1507, No. 1Expert Opinion on Pharmacotherapy, Vol. 15, No. 16 Volume 26Issue 1 Winter 2014Pages E26-E26 Metrics PDF download History Published online 1 January 2014 Published in print 1 January 2014" @default.
• W2042990257 created "2016-06-24" @default.
• W2042990257 creator A5043939107 @default.
• W2042990257 creator A5078777744 @default.
• W2042990257 date "2014-01-01" @default.
• W2042990257 modified "2023-09-27" @default.
• W2042990257 title "Improvement in Psychotic Symptoms and Social Functioning After Augmentation of Paliperidone With Clozapine in a Patient With Schizoaffective Disorder" @default.
• W2042990257 doi "https://doi.org/10.1176/appi.neuropsych.13010010" @default.
• W2042990257 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24515699" @default.
• W2042990257 hasPublicationYear "2014" @default.
• W2042990257 type Work @default.
• W2042990257 sameAs 2042990257 @default.
• W2042990257 citedByCount "4" @default.
• W2042990257 countsByYear W20429902572014 @default.
• W2042990257 countsByYear W20429902572018 @default.
• W2042990257 countsByYear W20429902572020 @default.
• W2042990257 crossrefType "journal-article" @default.
• W2042990257 hasAuthorship W2042990257A5043939107 @default.
• W2042990257 hasAuthorship W2042990257A5078777744 @default.
• W2042990257 hasConcept C118552586 @default.
• W2042990257 hasConcept C15744967 @default.
• W2042990257 hasConcept C2776412080 @default.
• W2042990257 hasConcept C2776619155 @default.
• W2042990257 hasConcept C2777126507 @default.
• W2042990257 hasConcept C2778528637 @default.
• W2042990257 hasConcept C2779727114 @default.
• W2042990257 hasConcept C2780057945 @default.
• W2042990257 hasConcept C2780211496 @default.
• W2042990257 hasConcept C2780325297 @default.
• W2042990257 hasConcept C2780494398 @default.
• W2042990257 hasConcept C2780864610 @default.
• W2042990257 hasConcept C70410870 @default.
• W2042990257 hasConcept C71924100 @default.
• W2042990257 hasConceptScore W2042990257C118552586 @default.
• W2042990257 hasConceptScore W2042990257C15744967 @default.
• W2042990257 hasConceptScore W2042990257C2776412080 @default.
• W2042990257 hasConceptScore W2042990257C2776619155 @default.
• W2042990257 hasConceptScore W2042990257C2777126507 @default.
• W2042990257 hasConceptScore W2042990257C2778528637 @default.
• W2042990257 hasConceptScore W2042990257C2779727114 @default.
• W2042990257 hasConceptScore W2042990257C2780057945 @default.
• W2042990257 hasConceptScore W2042990257C2780211496 @default.
• W2042990257 hasConceptScore W2042990257C2780325297 @default.
• W2042990257 hasConceptScore W2042990257C2780494398 @default.
• W2042990257 hasConceptScore W2042990257C2780864610 @default.
• W2042990257 hasConceptScore W2042990257C70410870 @default.
• W2042990257 hasConceptScore W2042990257C71924100 @default.
• W2042990257 hasIssue "1" @default.
• W2042990257 hasLocation W20429902571 @default.
• W2042990257 hasLocation W20429902572 @default.
• W2042990257 hasOpenAccess W2042990257 @default.
• W2042990257 hasPrimaryLocation W20429902571 @default.
• W2042990257 hasRelatedWork W1985227454 @default.
• W2042990257 hasRelatedWork W2066030143 @default.
• W2042990257 hasRelatedWork W2172660303 @default.
• W2042990257 hasRelatedWork W2252986970 @default.
• W2042990257 hasRelatedWork W2258976781 @default.
• W2042990257 hasRelatedWork W2540269208 @default.
• W2042990257 hasRelatedWork W2909861142 @default.
• W2042990257 hasRelatedWork W3102273891 @default.
• W2042990257 hasRelatedWork W3119216916 @default.
• W2042990257 hasRelatedWork W4206122324 @default.
• W2042990257 hasVolume "26" @default.
• W2042990257 isParatext "false" @default.
• W2042990257 isRetracted "false" @default.
• W2042990257 magId "2042990257" @default.
• W2042990257 workType "article" @default.